Low-intensity extracorporeal shock wave-based cardiac regeneration therapy: Low-intensity extracorporeal shock wave suppresses tumor suppressor INK4a/p16 expression, inhibits dilated cardiomyopathy and heart failure and extends life span via up regulation of its target gene, 18/May/2017, 7.46 pm

Natural product-derived therapy for Metastatic human tumors: Bauerenol, isolated from herb Suregada angustifolia, decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via up regulation of its target gene, 18/February/2017, 7.26 am
May 18, 2017
Natural product therapy for pulmonary arterial hypertension: Silymarin, isolated from M.Thistle, inhibits the development of pulmonary arterial hypertension via down regulation of Notch3 and its target gene Hes-5, 18/May/2017, 11.58 pm
May 18, 2017
Show all

Introduction: What they say

A recent study from the Stem Cell Aging Group, Centro Nacional de Investigaciones Cardiovasculares, E-28029 Madrid, Spain shows that “Bmi1 limits dilated cardiomyopathy and heart failure by inhibiting cardiac senescence.” This study was published in the online journal 9 March 2015 issue of  Nature Communications by Prof Gonzalez, Gonzalez-Valdes and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Low-intensity extracorporeal shock wavebased cardiac regeneration therapy: Low-intensity extracorporeal shock wave suppresses tumor suppressor INK4a/p16 expression, inhibits dilated cardiomyopathy  and heart failure and extends life span via up regulation of its target gene

Price 100


From the Significance of the study to Public health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) Dilated cardiomyopathy is the leading cause of Heart failure; (3) the raise  of death rate, due to cardiovascular disease, has increased from 12.3 million in 1990 to 17.3 million in 2013; (4) 13% of cardiovascular disease occur due to  uncontrolled high blood pressure; (5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) 85% of people over  80 years are susceptible to cardiovascular diseases; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (8) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; and (9) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find:  (i) a cure to diseases, as mentioned above, leading to cardiovascular disease; (ii) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (iii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From research findings to therapeutic opportunity:

This study suggests, for the first time, that Low-intensity extracorporeal shock wave therapy, by increasing the expression of its target genes, it may suppress the expression of tumor suppressor  and the ageing marker INK4a/p16 (figure 1).

Thereby, it may: (1) inhibit cardiac senescence; (2) increase regenerative potential in aged tissues; and (3) improve ventricular dimensions and contractility.

Thus,  by subjecting myocardial patients to Low-intensity extracorporeal shock wave therapy, one may prevent Dilated cardiomyopathy and ageing-associated (or, stress-associated) decline in cardiac function.

Based on this finding, physicians/cardiologists may consider adapting  Low-intensity extracorporeal shock wave therapy (figure 1) in the treatment of Dilated cardiomyopathy and ageing-associated cardiac dysfunction.

Figure 1. Mechanistic insight into how Low-intensity extracorporeal shock wave therapy may aid in cardiac protection and promote longevity. Low-intensity extracorporeal shock wave therapy inhibits dilated cardiomyopathy and heart failure via down regulation of ageing/senescence marker INK4a


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How  Low-intensity extracorporeal shock wave therapy suppresses the expression of tumor suppressor INK4a/p16.

# Research cooperation

Amount: $300

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L., Low-intensity extracorporeal shock wave-based cardiac regeneration therapy: Low-intensity extracorporeal shock wave suppresses tumor suppressor INK4a/p16 expression, inhibits dilated cardiomyopathy  and heart failure and extends life span via up regulation of its target gene, 18/May/2017, 7.46 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.